A US Food and Drug Administration (FDA) panel has recommended what could pave the way for the world's first drug to treat lack of sexual desire in women by mid-August.
The advisory committee has backed the approval of flibanserin, a drug that is counterpart to Viagra - the widely used drug for male erectile dysfunction, the New York Times reported.
The drug could potentially be approved by August 18 - the FDA deadline - this year. The US agency usually follows the advice of its advisory committees.
"The unmet need seems to be so strong that even for a drug with rather modest benefit, I think approving the product with strong limitations seems to be the right step at this point," Tobias Gerhard, a committee member and expert on drug safety at Rutgers University in New Jersey, was quoted as saying.
![Use of Viagra and Other Related Drugs Not Universal]( "Use of Viagra and Other Related Drugs Not Universal")
Taking oral phosphodiesterase type 5 inhibitors to treat erectile dysfunction and impotency may increase sexual activity but it cannot give satisfaction.
The pink pill, taken once a day at bedtime, would be approved for pre-menopausal women suffering a lack of sexual desire that causes them distress.
Nearly seven percent of pre-menopausal women have this condition called hypoactive sexual desire disorder.
The drug works by influencing the level of certain chemicals like serotonin and dopamine in the brain.
Women who took part in three clinical trials had an average of two to three of what they defined as "sexually satisfying events" per month.
Once they started taking the drug, the number of such events increased.
Women on flibanserin also reported feeling more desire.
However, the side effects like low blood pressure and fainting should be taken into account while prescribing the drug for women, the trial studies suggested.
The move has been hailed by some women's organisations as a step toward sexual equality.
"Today, we write a new chapter in the fight for equity in sexual health," Susan Scanlan, chairwoman of the Even the Score coalition, said in a statement.
Source: Medindia
Use of Viagra and Other Related Drugs Not Universal 'Cure-All' for Impotency
Taking oral phosphodiesterase type 5 inhibitors to treat erectile dysfunction and impotency may increase sexual activity but it cannot give satisfaction.
The pink pill, taken once a day at bedtime, would be approved for pre-menopausal women suffering a lack of sexual desire that causes them distress.
Nearly seven percent of pre-menopausal women have this condition called hypoactive sexual desire disorder.
The drug works by influencing the level of certain chemicals like serotonin and dopamine in the brain.
Women who took part in three clinical trials had an average of two to three of what they defined as "sexually satisfying events" per month.
Once they started taking the drug, the number of such events increased.
Women on flibanserin also reported feeling more desire.
However, the side effects like low blood pressure and fainting should be taken into account while prescribing the drug for women, the trial studies suggested.
The move has been hailed by some women's organisations as a step toward sexual equality.
"Today, we write a new chapter in the fight for equity in sexual health," Susan Scanlan, chairwoman of the Even the Score coalition, said in a statement.
Source: Medindia
Anti-Cancer, Anti-Alzheimer's Properties Found in Viagra
A new study has revealed that if Viagra is used with new drugs,it can have anti-cancer, antibacterial, and therapeutic effects.
 Caffeine and Viagra Save Prematurely Born InfantsMedications like Sildenafil and Caffeine are used in comprehensive care for prematurely born children, this fact is not known to many people. |
Latest Women Health News
In 2021, Japan has an increased incidence of low birth weight estimated at 9.2% for all births.
The higher suicide risk for bisexual women is associated with increased greater discrimination.
Women over 45 years old taking estrogen pills have a higher likelihood of developing high blood pressure compared to those using transdermal or vaginal formulations.
The new study assessed the beneficial effects of nitroglycerin patches in treating hot flashes in postmenopausal women.
A new study investigated the rate of neural tube defects in predominantly Hispanic-populated women before and after the voluntary fortification of corn masa flour with folic acid.
